Table 1 Correlation between serum miR-377 expression levels and clinicopathological parameters in ESCC
From: MicroRNA-377 suppresses initiation and progression of esophageal cancer by inhibiting CD133 and VEGF
Variable | n | Serum miR-377 expression a | P-value | |
---|---|---|---|---|
Low | High | |||
Age (years) | ||||
⩽55 | 20 | 9 | 11 | |
⩾55 | 94 | 48 | 46 | 0.622 |
Gender | ||||
Female | 12 | 6 | 6 | |
Male | 102 | 51 | 51 | 1.000 |
pT-stage | ||||
0/1/2 | 66 | 26 | 40 | |
3/4 | 26 | 20 | 6 | 0.001 |
pN-stage | ||||
0 | 53 | 25 | 28 | |
1/2/3 | 39 | 21 | 18 | 0.526 |
pM-stage | ||||
0 | 84 | 38 | 46 | |
1 | 7 | 7 | 0 | 0.0007 |
Pathologic stage | ||||
pCRb | 22 | 6 | 16 | |
Othersc/I/II/III/IV | 70 | 40 | 30 | 0.014 |
Pathologic stage | ||||
pCRb/Othersc | 34 | 11 | 23 | |
I/II/III/IV | 58 | 35 | 23 | 0.009 |
R category | ||||
R0 | 80 | 37 | 43 | |
R1 | 12 | 10 | 2 | 0.016 |